A Study to Follow-up Patients With End Stage Renal Disease Undergoing Hemodialysis, Receiving Selective Vitamin D Receptor Activator's for Prevention and Treatment of Secondary Hyperparathyroidism

Inclusion Criteria: * Patients with secondary hyperparathyroidism in the presence of chronic kidney disease stage 5 and receiving hemodialysis who is treated with sVDRA's (Selective Vitamin D Receptor Activator) injection * iPTH (intact parathyroid hormone) \>300pg/ml, corrected serum Ca (Calcium) \< 10.2 mg/dl, serum P (Phosphorus) \< 6 mg/dl * Male and female (not pregnant or not planning to be pregnant in the next 12 months) patients equal to or older than 18 years of age * Signed Informed consent by subject * Hypertensive and Diabetic subjects must be on an optimal and steady medication regimen for more than 30 days Exclusion Criteria: * Subject has known hypersensitivity and/or toxicity to vitamin D metabolites and/or other product ingredients * Subject has participated in a clinical study within the last month * If sVDRA's (Selective Vitamin D Receptor Activator) are contraindicated according to the SmPC (Summary of Product Characteristics)